Bayer Roundup Settlement Proposed Amid Appeal
Bayer Roundup settlement proposal shifts legal risk as the U.S. Supreme Court readies an appeal; investors eye liability and strategy.
KEY TAKEAWAYS
- Bayer proposed a $10.5B settlement combining a $7.5B class fund and $3B for existing U.S. cases.
- The framework covers roughly 67,000 outstanding claims and includes no admission of wrongdoing or liability.
- It was framed alongside a pending Supreme Court appeal of a $1.25M 2023 verdict, complicating Bayer's legal exposure.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Bayer AG proposed a $10.5 billion settlement on February 17, 2026, as the U.S. Supreme Court prepares to hear the company’s appeal of a 2023 verdict. The move reshapes the legal stakes in the long-running glyphosate litigation tied to its Roundup herbicide.
Settlement Terms and Legal Strategy
The proposed settlement includes a $7.5 billion Missouri state-court class fund covering claims over 20 years and $3 billion to resolve existing individual U.S. cases. Bayer has not admitted wrongdoing or liability in connection with the settlement.
The company faces roughly 67,000 outstanding claims alleging that long-term glyphosate exposure caused non-Hodgkin lymphoma. Bayer has already paid more than $10 billion in verdicts and settlements since acquiring Monsanto for $66 billion, inheriting the litigation.
In January 2026, the U.S. Supreme Court agreed to hear Bayer’s appeal of a 2023 Missouri jury verdict of $1.25 million. The appeal raises federal-preemption questions central to Bayer’s defense, which cites the U.S. Food and Drug Administration’s finding that glyphosate is not a carcinogen.
CEO Bill Anderson described the class settlement as an important addition to Bayer’s Supreme Court case and said he is considering whether to stop producing glyphosate because of the litigation burden. The settlement’s structure reflects a dual legal strategy: it aims to manage future claims through a long-term mechanism while the Supreme Court determines whether federal law limits some state-law claims. This decision could significantly affect the geographic and legal scope of Bayer’s liability in Roundup litigation.
